Ascletis Pharma Inc
HKEX:1672

Watchlist Manager
Ascletis Pharma Inc Logo
Ascletis Pharma Inc
HKEX:1672
Watchlist
Price: 1.6 HKD -5.33% Market Closed
Market Cap: 1.6B HKD
Have any thoughts about
Ascletis Pharma Inc?
Write Note

Ascletis Pharma Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ascletis Pharma Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Ascletis Pharma Inc
HKEX:1672
Cash from Financing Activities
-ÂĄ81.5m
CAGR 3-Years
-56%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash from Financing Activities
ÂĄ2.6B
CAGR 3-Years
-57%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Cash from Financing Activities
ÂĄ960.9m
CAGR 3-Years
-31%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Financing Activities
-ÂĄ893.3m
CAGR 3-Years
N/A
CAGR 5-Years
-98%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cash from Financing Activities
-ÂĄ1.2B
CAGR 3-Years
-25%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash from Financing Activities
-ÂĄ2B
CAGR 3-Years
24%
CAGR 5-Years
-38%
CAGR 10-Years
-39%
No Stocks Found

Ascletis Pharma Inc
Glance View

Market Cap
1.6B HKD
Industry
Biotechnology

Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

Intrinsic Value
0.7 HKD
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Ascletis Pharma Inc's Cash from Financing Activities?
Cash from Financing Activities
-81.5m CNY

Based on the financial report for Dec 31, 2023, Ascletis Pharma Inc's Cash from Financing Activities amounts to -81.5m CNY.

What is Ascletis Pharma Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-56%

Over the last year, the Cash from Financing Activities growth was -5 643%. The average annual Cash from Financing Activities growth rates for Ascletis Pharma Inc have been -56% over the past three years .

Back to Top